Consolidated Statements of Cash Flows (unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (9,276)	$ (10,861)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of Portamedic and subsidiary	(3,618)	0
Depreciation	1,828	2,970
Amortization	0	159
Amortization of debt financing fees	213	102
Provision for bad debt expense	80	55
Share-based compensation expense	581	539
Impairment and loss on disposal of fixed assets	486	208
Change in assets and liabilities:
Accounts receivable	955	(171)
Inventories	(598)	(512)
Other assets	(155)	1,053
Accounts payable, accrued expenses and other long-term liabilities	1,718	1,311
Net cash used in operating activities	(7,786)	(5,147)
Cash flows from investing activities:
Capital expenditures	(1,062)	(3,346)
Costs paid to sell Portamedic	(411)	0
Proceeds from the sale of Portamedic	6,053	0
Proceeds from sale of equipment	0	51
Net cash provided by (used in) investing activities	4,580	(3,295)
Cash flows from financing activities:
Cumulative borrowings under credit facility	49,023	0
Cumulative payments under credit facility	(46,415)	0
Reduction in capital lease obligations	(113)	(214)
Proceeds related to the exercise of stock options	14	0
Debt financing fees	(967)	(100)
Net cash provided by (used in) financing activities	1,542	(314)
Net decrease in cash and cash equivalents	(1,664)	(8,756)
Cash and cash equivalents at beginning of period	8,319	16,917
Cash and cash equivalents at end of period	6,655	8,161
Supplemental disclosure of non-cash investing activities:
Fixed assets vouchered but not paid	556	570
Fixed assets acquired by capital lease	74	0
Costs to sell Portamedic but not paid	534	0
Supplemental disclosure of cash paid during period for:
Income taxes	$ 52	$ 40